NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Th… Read more
Market Cap & Net Worth: NewAmsterdam Pharma Company N.V. Warrant (NAMSW)
NewAmsterdam Pharma Company N.V. Warrant (NASDAQ:NAMSW) has a market capitalization of $177.38K ($177.38K) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6751 globally and #3715 in its home market, demonstrating a 0.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NewAmsterdam Pharma Company N.V. Warrant's stock price $18.50 by its total outstanding shares 9588 (9.59K).
NewAmsterdam Pharma Company N.V. Warrant Market Cap History: 2021 to 2026
NewAmsterdam Pharma Company N.V. Warrant's market capitalization history from 2021 to 2026. Data shows growth from $5.65K to $177.38K (19.60% CAGR).
NewAmsterdam Pharma Company N.V. Warrant Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NewAmsterdam Pharma Company N.V. Warrant's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
NewAmsterdam Pharma Company N.V. Warrant's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $8.32K | $102.69 Million | -$22.63 Million | 0.00x | N/A |
| 2023 | $30.01K | $14.09 Million | -$176.94 Million | 0.00x | N/A |
| 2024 | $138.74K | $45.56 Million | -$241.60 Million | 0.00x | N/A |
Competitor Companies of NAMSW by Market Capitalization
Companies near NewAmsterdam Pharma Company N.V. Warrant in the global market cap rankings as of March 19, 2026.
Key companies related to NewAmsterdam Pharma Company N.V. Warrant by market ranking:
- Fibra Terrafina (PINK:CBAOF): Ranked #6742 globally with a market cap of $1.16 Billion USD.
- Wuhan Raycus Fiber Laser Technologies Co Ltd Class A (SHE:300747): Ranked #6743 globally with a market cap of $1.16 Billion USD ( CN¥8.49 Billion CNY).
- ACC Limited (NSE:ACC): Ranked #6752 globally with a market cap of $1.16 Billion USD ( ₹100.04 Billion INR).
- Beijing Cisri Gaona Materials Tech (SHE:300034): Ranked #6753 globally with a market cap of $1.15 Billion USD ( CN¥8.47 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #6742 | Fibra Terrafina | PINK:CBAOF | $1.16 Billion | $1.50 |
| #6743 | Wuhan Raycus Fiber Laser Technologies Co Ltd Class A | SHE:300747 | $1.16 Billion | CN¥29.92 |
| #6752 | ACC Limited | NSE:ACC | $1.16 Billion | ₹1405.20 |
| #6753 | Beijing Cisri Gaona Materials Tech | SHE:300034 | $1.15 Billion | CN¥19.85 |
NewAmsterdam Pharma Company N.V. Warrant Historical Marketcap From 2021 to 2026
Between 2021 and today, NewAmsterdam Pharma Company N.V. Warrant's market cap moved from $5.65K to $ 177.38K, with a yearly change of 19.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $177.38K | -19.57% |
| 2025 | $220.52K | +58.95% |
| 2024 | $138.74K | +362.30% |
| 2023 | $30.01K | +260.60% |
| 2022 | $8.32K | +47.37% |
| 2021 | $5.65K | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of NewAmsterdam Pharma Company N.V. Warrant was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $177.38K USD |
| MoneyControl | $177.38K USD |
| MarketWatch | $177.38K USD |
| marketcap.company | $177.38K USD |
| Reuters | $177.38K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.